Biotechnology company
Appears in 1 story
Clinical-stage biotech, TSE-listed (7827), trispecific immunotherapies for oncology
The U.S. Food and Drug Administration cleared HanchorBio's investigational new drug application for HCB303, a single fusion protein that blocks three immune pathways: TIGIT, PD-L1, and CD47. The October 5 clearance lets the Taipei-based biotech open a Phase 1 trial in patients with advanced solid tumors who have exhausted standard options.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
